Efficacy and Safety of Dapagliflozin versus Liraglutide in Patients with Overweight or Obesity and Type 2 Diabetes Mellitus: A Randomised Controlled Clinical Trial in Tianjin, China

Table 3

Changes in other metabolic indicators (body weight, Tg, LDL-C, DBP, and SBP) at week 24.

Parameter	Liraglutide	Dapagliflozin
Body weight (kg)
Baseline
Week 24
Change from baseline^a	-0.08 (-1.78~1.94)	-0.61 (-1.23~0.01)
value	-0.086	1.939
value	0.931	0.055
SBP (mmHg)
Baseline
Week 24
Change from baseline^a	-3.98 (-8.87~0.92)	-5.28 (-8.43~-2.12)
value	1.608	3.306
value	0.111	0.001
DBP (mmHg)
Baseline
Week 24
Change from baseline^a	0.38 (2.92~-1.28)	-1.12 (-2.91~0.67)
value	-0.296	1.233
value	0.767	0.220
Tg (mmol/l)
Baseline
Week 24
Change from baseline^a	-0.24 (-0.49~0.01)	-0.15 (-0.49~0.18)
value	1.974	0.907
value	0.053	0.367
LDL-C (mmol/l)
Baseline
Week 24
Change from baseline^a	-0.24 (-0.49~0.02)	-0.24 (-0.42~-0.05)
value	1.837	2.512
value	0.071	0.014

Abbreviations: SBP: systolic blood pressure; DBP: diastolic blood pressure; Tg: triglycerides; LDL-C: low-density lipoprotein cholesterol. ^aMean change (95% confidence interval).